A pilot open-label clinical trial to evaluate decrease of brain amyloid beta(A-beta) by removing blood AB

A pilot open-label clinical trial to evaluate decrease of brain amyloid beta(A-beta) by removing blood A-beta - A pilot open-label clinical trial to evaluate decrease of brain amyloid beta (A-beta) by removing blood A-beta

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs042180148

Enrollment

Registered

2019-03-29

Start date

2018-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease, Mild Cognitive Impairment due to AD amyloid beta

Interventions

extracorporeal blood purification

blood purification

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non-diabetic MCI or mild AD of brain A-beta positive

Exclusion criteria

Exclusion criteria: 1) diabetes 2) abnormal numbers of platelets or erythrocytes, 3) complication such as severe circulatory failure and heart failure, 4) medical histroy of cerebral vascular disease (infarct, hemorrhage)

Design outcomes

Primary

Measure	Time frame
Change of brain A-beta accumulation measured by PiB/PET	—

Secondary

Measure	Time frame
Change of cognitive functions (MMSE,WMS-R, GDS, ADAS-JCog)	—

Contacts

Public ContactMidori Hasegawa

Fujita Health University Hospital

mhase@fujita-hu.ac.jp+81-562-93-9009

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026